Please disable your adblock and script blockers to view this page

HIV is reported cured in a second patient, a milestone in the global AIDS epidemic


byScientists
Apoorva MandavilliFor
Opportunistic Infections
the University Medical Center Utrecht
the Science Times
Facebook
Wensing
IciStem
AMFAR
The New York Times
the University of California
University College London
the National Institute of Allergy
H.I.V. infection.)Mr


H.I.V.
Annemarie Wensing
Timothy Ray Brown
H.I.V.In
Steven Deeks
Ravindra Gupta
Anthony Fauci
Jiankui
H.I.V. —
Mike McCune
Bill
Melinda Gates Foundation
Timothy J. Henrich


European
American
German
Northern European

No matching tags

No matching tags


London
Seattle
Netherlands
Berlin
Palm Springs
Calif
San Francisco
H.I.V.
Düsseldorf
China

No matching tags

Positivity     37.00%   
   Negativity   63.00%
The New York Times
SOURCE: https://www.nytimes.com/2019/03/04/health/aids-cure-london-patient.html
Write a review: Google News
Summary

With the so-called London patient, they seem to have succeeded.By Apoorva MandavilliFor just the second time since the global epidemic began, a patient appears to have been cured of infection with H.I.V., the virus that causes AIDS.The news comes nearly 12 years to the day after the first patient known to be cured, a feat that researchers have long tried, and failed, to duplicate. Once it became clear that Mr. Brown was cured, scientists set out to duplicate his result with other cancer patients infected with H.I.V.In case after case, the virus came roaring back, often around nine months after the patients stopped taking antiretroviral drugs, or else the patients died of cancer. He, too, received immunosuppressive drugs, but the treatment was much less intense, in line with current standards for transplant patients.He quit taking anti-H.I.V. drugs in September 2017, making him the first patient since Mr. Brown known to remain virus-free for more than a year after stopping.“I think this does change the game a little bit,” said Dr. Ravindra Gupta, a virologist at University College London who presented the findings at the Seattle meeting. “These dreams are motivated by cases like this — it helps us to imagine what might be done in the future.”One important caveat to any such approach is that the patient would still be vulnerable to a form of H.I.V. called X4, which employs a different protein, CXCR4, to enter cells.“This is only going to work if someone has a virus that really only uses CCR5 for entry — and that’s actually probably about 50 percent of the people who are living with H.I.V., if not less,” said Dr. Timothy J.

As said here by Apoorva Mandavilli